|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0178499,
umls-concept:C0185117,
umls-concept:C0205179,
umls-concept:C0205276,
umls-concept:C0245726,
umls-concept:C0380603,
umls-concept:C0449258,
umls-concept:C0684249,
umls-concept:C1517927,
umls-concept:C1519316,
umls-concept:C1527178,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2911684
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-10-5
|
|
pubmed:abstractText |
No biologic signature of chemoradiotherapy sensitivity has been reported for patients with locally advanced non-small-cell lung cancer (NSCLC). We have previously demonstrated that basic fibroblast growth factor (FGF-2) and alphavbeta3 integrin pathways control tumor radioresistance. We investigated whether the expression of the proteins involved in these pathways might be associated with the response to treatment and, therefore, the clinical outcome.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
696-702
|
|
pubmed:meshHeading |
pubmed-meshheading:19386436-Adult,
pubmed-meshheading:19386436-Aged,
pubmed-meshheading:19386436-Angiopoietin-2,
pubmed-meshheading:19386436-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19386436-Combined Modality Therapy,
pubmed-meshheading:19386436-Disease Progression,
pubmed-meshheading:19386436-Disease-Free Survival,
pubmed-meshheading:19386436-Female,
pubmed-meshheading:19386436-Fibroblast Growth Factor 2,
pubmed-meshheading:19386436-Humans,
pubmed-meshheading:19386436-Integrin beta3,
pubmed-meshheading:19386436-Lung Neoplasms,
pubmed-meshheading:19386436-Male,
pubmed-meshheading:19386436-Middle Aged,
pubmed-meshheading:19386436-Neoplasm Proteins,
pubmed-meshheading:19386436-Neoplasm Recurrence, Local,
pubmed-meshheading:19386436-Proportional Hazards Models,
pubmed-meshheading:19386436-Radiation Tolerance,
pubmed-meshheading:19386436-Syndecan-1
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.
|
|
pubmed:affiliation |
Département de Radiothérapie, Institut Claudius Regaud, 20-24 rue du Pont St. Pierre, Toulouse Cedex, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
